Modification of Parkinsonism--chronic treatment with L-dopa.
about
Available and emerging treatments for Parkinson's disease: a reviewLevodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatmentEditorial: Dopa decarboxylase inhibitorsNeuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesMerging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's diseaseParkinson's disease: gene therapiesPreservation of function in Parkinson's disease: what's learning got to do with it?Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.Drug elucidation: invertebrate genetics sheds new light on the molecular targets of CNS drugs.Monoaminergic and Histaminergic Strategies and Treatments in Brain DiseasesManganese-Induced Parkinsonism and Parkinson's Disease: Shared and Distinguishable FeaturesPossible mechanism of adverse reaction following levodopa plus benserazide treatmentCardiovascular effects of levodopa in aged versus younger patients with Parkinson's diseaseParkinson's disease and levodopa. A five-year follow-up and reviewComparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's diseaseMiosis during L-dopa therapyTetraspanin (TSP-17) protects dopaminergic neurons against 6-OHDA-induced neurodegeneration in C. elegansDr Lewis Kitchener Dahl, the Dahl rats, and the "inconvenient truth" about the genetics of hypertensionNeuroanatomical study of the A11 diencephalospinal pathway in the non-human primateDisease-toxicant interactions in Parkinson's disease neuropathologyMortality in levodopa-treated Parkinson's disease.Frequency-velocity mismatch: a fundamental abnormality in parkinsonian gait.Effect of L-dopa on speech in Parkinsonism. An EMG study of labial articulatory functionThe role of GRK6 in animal models of Parkinson's disease and L-DOPA treatmentParallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice.The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan AfricaDevelopment of new levodopa treatment strategies in Parkinson's disease-from bedside to bench to bedsideDistinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia.Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation.Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease.The on-off phenomenonParkinson's disease--levodopa complications.Levodopa's awakening effect on patients with Parkinsonism.Kantamaneni BD, Curzon G:Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSFDoes levodopa alter depression and psychopathology in Parkinsonism patients?Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?Management of parkinson's disease--combined therapy with levodopa and thalamotomy.Neurotransmitter replacement therapy in Alzheimer's disease.Orofacial dyskinesia. Clinical features, mechanisms and drug therapyModification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.
P2860
Q24633444-A0C1291E-B10F-4BE3-92DF-CAD329F0CDCBQ24647141-612334C5-7A5C-4217-8365-55B9CB8779B7Q24673226-B2F4F2DE-59D1-4D59-B038-F1E02BDEC4E3Q26747508-7E824434-366F-4E91-B0F2-83A53EE3C447Q26773485-C2A0E0CF-88BD-43B3-B1B5-00D64D05D790Q26824184-0D2C34E5-5B1B-4BA5-935E-E52BB4452FA8Q26853387-00B390BF-9CD2-4712-8419-5A9DED9D5CA5Q27322513-F5A2130A-E18B-465C-918F-828237E8CB48Q27693888-5D68207F-0119-495B-9977-8B222F7EFB77Q28066691-DF9CD83A-9CDF-43B5-89CF-5B7F99B212F4Q28082230-6D989E15-B41A-4E75-97A5-53AB199C5E18Q28332309-375CF59C-6DF6-422F-A534-0862B786FB38Q28342014-04B21479-DD72-47EC-962D-AD9129FBFC0CQ28363594-4A5327B6-E9E3-42E5-9857-353E1D5D52CBQ28364195-57B0AD99-ECEC-4DEA-B771-B816C0C3B39CQ28365240-6D7026AA-FD3B-4E17-9881-B81DD3A1D1B4Q28542478-15868550-6E5C-4F94-835B-0BA4E5D30720Q28649829-BDA562F0-BAC5-40A6-B58A-7AF440A35DA5Q28748883-5AA0007A-612F-4E4F-8DDF-4F71AFAE0F7BQ29248297-6D50DDE1-458C-4A08-AF7C-0FFDA60B535BQ30414368-0E53B899-98CE-4605-80AE-CD1332A6BFC1Q30476731-492E9C86-C559-4753-9AE6-A92D10A4806AQ30496141-33A5DF71-653E-444D-9968-EFE568C3FDE4Q30506209-D45FA269-4278-43B3-B2CA-637EA7CF61C2Q30538394-6D133B83-B14A-4337-B5ED-CCA378EBCE41Q30586911-49D670A1-6143-4A6A-8339-F9EA5362711CQ30852749-B2A445A5-FE0E-41CD-AF67-589834C16806Q30988635-6F4C2297-46FA-47DB-A7AE-D3E2680F32A4Q32134305-46B6FD88-2BF3-452E-A787-7FA97E0F6F76Q33619721-EAB9DABE-BB35-4DCF-82CC-2E2FC8836289Q33631685-A8EF1C6A-9021-4442-84E9-A507BD227F98Q33714114-C7E8C11C-4AEE-49DD-8D9A-D0742E9C22E8Q33756468-4CD65BE8-2CBA-4C96-8EF7-A40BB47A5DB9Q33756474-48A48537-F5D2-4675-AB62-32FAE28302E2Q33756784-45C5E412-13BC-4383-A0D0-9BB83353B1E3Q33761790-2DB47F5E-273D-43AA-BB9E-3FD4E55CC0DBQ33824385-B4406F37-EDC0-452C-B2E3-7664D3714C62Q33921314-0340D5E2-DD99-4A08-80CD-C23664CF4811Q34050289-A4BA24E5-56E7-414B-BFD3-3328253D95CCQ34062205-CF3305C9-205F-4CA5-8161-CB0ED7256DF2
P2860
Modification of Parkinsonism--chronic treatment with L-dopa.
description
1969 nî lūn-bûn
@nan
1969年の論文
@ja
1969年学术文章
@wuu
1969年学术文章
@zh
1969年学术文章
@zh-cn
1969年学术文章
@zh-hans
1969年学术文章
@zh-my
1969年学术文章
@zh-sg
1969年學術文章
@yue
1969年學術文章
@zh-hant
name
Modification of Parkinsonism--chronic treatment with L-dopa.
@en
Modification of Parkinsonism--chronic treatment with L-dopa.
@nl
type
label
Modification of Parkinsonism--chronic treatment with L-dopa.
@en
Modification of Parkinsonism--chronic treatment with L-dopa.
@nl
altLabel
Modification of Parkinsonism — Chronic Treatment with L-Dopa
@en
prefLabel
Modification of Parkinsonism--chronic treatment with L-dopa.
@en
Modification of Parkinsonism--chronic treatment with L-dopa.
@nl
P50
P1476
Modification of Parkinsonism--chronic treatment with L-dopa.
@en
P304
P356
10.1056/NEJM196902132800701
P4011
f5ed1c470f0cf88b4422ae16e710768f8be5d753
P407
P577
1969-02-01T00:00:00Z